Cargando…

Thalidomide affects limb formation and multiple myeloma related genes in human induced pluripotent stem cells and their mesoderm differentiation

Although thalidomide is highly teratogenic, it has been prescribed for treating multiple myeloma and Hansen's disease. However, its mechanism of action is not fully understood. Here, we employed a reverse transcription quantitative PCR array to measure the expression of 84 genes in human induce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shimizu, Maho, Tachikawa, Saoko, Saitoh, Nagatsuki, Nakazono, Kohei, Yu-Jung, Liu, Suga, Mika, Ohnuma, Kiyoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973312/ https://www.ncbi.nlm.nih.gov/pubmed/33763605 http://dx.doi.org/10.1016/j.bbrep.2021.100978

Ejemplares similares

Imaging-cytometry revealed spatial heterogeneities of marker expression in undifferentiated human pluripotent stem cells
por: Suga, Mika, et al.
Publicado: (2016)

Enzyme-free Passage of Human Pluripotent Stem Cells by Controlling Divalent Cations
por: Ohnuma, Kiyoshi, et al.
Publicado: (2014)

Thalidomide and its analogues in the treatment of Multiple Myeloma
por: Latif, Tahir, et al.
Publicado: (2012)

Generation and trapping of a mesoderm biased state of human pluripotency
por: Stavish, Dylan, et al.
Publicado: (2020)

Mesodermal Derivatives of Pluripotent Stem Cells Route to Scarless Healing
por: Suzdaltseva, Yulia, et al.
Publicado: (2023)

Review of thalidomide in the treatment of newly diagnosed multiple myeloma
por: Cavallo, Federica, et al.
Publicado: (2007)

Adverse Effects of Thalidomide Administration, in Patients with Myeloma Multiplex?
por: Svetlana Balkanov, Krstevska, et al.
Publicado: (2014)

Thalidomide for the Treatment of Refractory Multiple Myeloma: Association of Plasma Concentrations of Thalidomide and Angiogenic Growth Factors with Clinical Outcome
por: Kakimoto, Tsunayuki, et al.
Publicado: (2002)

Constitutive Expression of Pluripotency-Associated Genes in Mesodermal Progenitor Cells (MPCs)
por: Pacini, Simone, et al.
Publicado: (2010)

Non-thermal atmospheric-pressure plasma potentiates mesodermal differentiation of human induced pluripotent stem cells
por: Kobayashi, Mime, et al.
Publicado: (2022)

Reversible Pulmonary Hypertension Related to Thalidomide Treatment for Multiple Myeloma
por: Villa, Antonio, et al.
Publicado: (2011)

Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide
por: Castro, T.B.M., et al.
Publicado: (2016)

Effect of thalidomide on bone marrow angiogenesis in multiple myeloma patients
por: Cury, Priscilla Cury de Camargo, et al.
Publicado: (2020)

Amnion signals are essential for mesoderm formation in primates
por: Yang, Ran, et al.
Publicado: (2021)

Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma
por: Iida, Shinsuke, et al.
Publicado: (2018)

Cell cycle regulators control mesoderm specification in human pluripotent stem cells
por: Yiangou, Loukia, et al.
Publicado: (2019)

Modeling human extraembryonic mesoderm cells using naive pluripotent stem cells
por: Pham, Thi Xuan Ai, et al.
Publicado: (2022)

Auto/paracrine factors and early Wnt inhibition promote cardiomyocyte differentiation from human induced pluripotent stem cells at initial low cell density
por: Le, Minh Nguyen Tuyet, et al.
Publicado: (2021)

Thalidomide Induced Nonspecific Interstitial Pneumonia in Patient with Relapsed Multiple Myeloma
por: Kang, Myung-Hee, et al.
Publicado: (2010)

Acute Pulmonary Toxicity from Thalidomide in a Patient with Multiple Myeloma
por: Khalsa, Satkirin K., et al.
Publicado: (2015)

The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma
por: Hashimoto, Shigeo, et al.
Publicado: (2016)

Clinical efficacy of Thalidomide combined with PAD Regimen in patients with multiple Myeloma
por: Wang, Yu, et al.
Publicado: (2023)

In Vitro Modeling of Paraxial Mesodermal Progenitors Derived from Induced Pluripotent Stem Cells
por: Sakurai, Hidetoshi, et al.
Publicado: (2012)

Tbx3 Controls Dppa3 Levels and Exit from Pluripotency toward Mesoderm
por: Waghray, Avinash, et al.
Publicado: (2015)

Depletion of Mageb16 induces differentiation of pluripotent stem cells predominantly into mesodermal derivatives
por: Gaspar, John Antonydas, et al.
Publicado: (2017)

Fgf signalling triggers an intrinsic mesodermal timer that determines the duration of limb patterning
por: Sedas Perez, Sofia, et al.
Publicado: (2023)

The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea
por: Kim, Cheolsu, et al.
Publicado: (2015)

Argonaute2 Is Essential for Mammalian Gastrulation and Proper Mesoderm Formation
por: Alisch, Reid S, et al.
Publicado: (2007)

From Dynamic Expression Patterns to Boundary Formation in the Presomitic Mesoderm
por: Tiedemann, Hendrik B., et al.
Publicado: (2012)

Neural-mesodermal progenitor interactions in pattern formation: an introduction to the collection
por: Kalcheim, Chaya, et al.
Publicado: (2014)

Thalidomide—Then and Now: Case Report of a Woman With Thalidomide Embryopathy and Review of Current Thalidomide Uses
por: Malik, Sara, et al.
Publicado: (2021)

Age-related changes in patients with upper limb thalidomide embryopathy in the United Kingdom
por: Markiewicz, Magdalena, et al.
Publicado: (2023)

Thalidomide upper limb embryopathy – pathogenesis, past and present management and future considerations
por: Vargesson, Neil, et al.
Publicado: (2023)

Human chondrogenic paraxial mesoderm, directed specification and prospective isolation from pluripotent stem cells
por: Umeda, Katsutsugu, et al.
Publicado: (2012)

Chalcone‐Supported Cardiac Mesoderm Induction in Human Pluripotent Stem Cells for Heart Muscle Engineering
por: Raad, Farah S., et al.
Publicado: (2021)

Modeling of intramembranous ossification using human pluripotent stem cell-derived paraxial mesoderm derivatives
por: Ikeda, Yuki, et al.
Publicado: (2023)

Therapeutic effects of thalidomide in myeloma are associated with the expression of fibroblast growth factor receptor 3
por: Qian, Shenxian, et al.
Publicado: (2005)

Nonspecific Interstitial Pneumonitis after Bortezomib and Thalidomide Treatment in a Multiple Myeloma Patient
por: Kang, Wonseok, et al.
Publicado: (2010)

Hemostatic changes after 1 month of thalidomide and dexamethasone therapy in patients with multiple myeloma
por: Robak, Marta, et al.
Publicado: (2012)

Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study
por: Garcia, M Kay, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_6lsek3ogi4fkq7uigdgmmou80p